107 related articles for article (PubMed ID: 4944951)
21. The effects of Staphylococcus aureus and Klebsiella pneumoniae peritonitis in mice exposed to normal and hypoxic conditions on red cell oxygen transport function.
Walker R; Wilder M; Valeri CR
J Med; 1975; 6(2):113-20. PubMed ID: 239991
[TBL] [Abstract][Full Text] [Related]
22. Reduction in the incidence of methicillin-resistant Staphylococcus aureus and ceftazidime-resistant Klebsiella pneumoniae following changes in a hospital antibiotic formulary.
Landman D; Chockalingam M; Quale JM
Clin Infect Dis; 1999 May; 28(5):1062-6. PubMed ID: 10452635
[TBL] [Abstract][Full Text] [Related]
23. Cefuroxime pharmacokinetics and pharmacodynamics for intravenous dosage regimens with 750 mg or 1500 mg doses in healthy young volunteers.
Thønnings S; Jensen KS; Nielsen NB; Skjønnemand M; Hansen DS; Lange KHW; Frimodt-Møller N
J Med Microbiol; 2020 Mar; 69(3):387-395. PubMed ID: 31958049
[No Abstract] [Full Text] [Related]
24. Klebsiella pneumoniae and Staphylococcus aureus infection in mice: difference in uremia and ammoniagenesis.
Walker RI; Chesbro W
Infect Immun; 1975 Sep; 12(3):571-5. PubMed ID: 1100523
[TBL] [Abstract][Full Text] [Related]
25. Perspective. Hospital-acquired infections: the problems of methicillin-resistant Staphylococcus aureus and infections with Klebsiella pneumoniae.
Finland M
Am J Med Sci; 1972 Sep; 264(3):207-11. PubMed ID: 4486504
[No Abstract] [Full Text] [Related]
26. Biofunctionalization of cellulosic fibres with L-cysteine: assessment of antibacterial properties and mechanism of action against Staphylococcus aureus and Klebsiella pneumoniae.
Caldeira E; Piskin E; Granadeiro L; Silva F; Gouveia IC
J Biotechnol; 2013 Dec; 168(4):426-35. PubMed ID: 24432376
[TBL] [Abstract][Full Text] [Related]
27. Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae and Escherichia coli: simulation of human plasma concentrations after intravenous dosage in an in vitro kinetic model.
Odenholt I; Cars O
J Antimicrob Chemother; 2006 Nov; 58(5):960-5. PubMed ID: 16936293
[TBL] [Abstract][Full Text] [Related]
28. Nosocomial pneumonia.
Preheim LC; Sanders WE
Compr Ther; 1981 Jun; 7(6):20-7. PubMed ID: 7018827
[No Abstract] [Full Text] [Related]
29. Studies on new antibiotic lividomycins. V. In vitro and in vivo antimicrobial activity of lividomycin A.
Kobayashi F; Nagoya T; Yoshimura Y; Kaneko K; Ogata SI
J Antibiot (Tokyo); 1972 Feb; 25(2):128-36. PubMed ID: 4624613
[No Abstract] [Full Text] [Related]
30. Pyrrole antibacterial agents. 1. Compounds related to pyoluteorin.
Bailey DM; Johnson RE; Salvador UJ
J Med Chem; 1973 Nov; 16(11):1298-300. PubMed ID: 4201184
[No Abstract] [Full Text] [Related]
31. Penicillins and cephalosporins from isothiazolylacetic acids.
Raap R; Micetich RG
J Med Chem; 1968 Jan; 11(1):70-3. PubMed ID: 4384130
[No Abstract] [Full Text] [Related]
32. In vivo antibacterial activity of cefodizime, a new cephalosporin antibiotic.
Kasai K; Tsuji A; Miyazaki S; Goto S; Fujimoto K; Masuyoshi S; Arai S
Jpn J Antibiot; 1984 Jul; 37(7):1306-12. PubMed ID: 6092740
[TBL] [Abstract][Full Text] [Related]
33. [Biological importance of the anti-carnosine activity of bacteria].
Bukharin OV; Stadnikov AA; Chernova OL; Kirgizova SB; Kovbyk LV; Boldyrev AA
Zh Mikrobiol Epidemiol Immunobiol; 2000; (4 Suppl):56-9. PubMed ID: 12712514
[TBL] [Abstract][Full Text] [Related]
34. [Bacteriological studies on prolinomethyltetracycline].
Kawarajo K; Onoda M; Nomiya B; Abe M
Jpn J Antibiot; 1971 Dec; 24(6):249-55. PubMed ID: 4946846
[No Abstract] [Full Text] [Related]
35. [Antibacterial in vitro and in vivo activity of a new tetracycline: CL 59806].
Renzini G; Bevilacqua RL; Boemi G; Ravagnan L
Antibiotica; 1967 Dec; 5(4):241-61. PubMed ID: 4900571
[No Abstract] [Full Text] [Related]
36. Combination therapy: a way to limit emergence of resistance?
Michéa-Hamzehpour M; Pechère JC; Marchou B; Auckenthaler R
Am J Med; 1986 Jun; 80(6B):138-42. PubMed ID: 3088999
[TBL] [Abstract][Full Text] [Related]
37. Chemical modification of erythromycin antibiotics. 4. Structure-activity relationships of erythromycin esters.
Martin YC; Jones PH; Perun TJ; Grundy WE; Bell S; Bower RR; Shipkowitz NL
J Med Chem; 1972 Jun; 15(6):635-8. PubMed ID: 4555493
[No Abstract] [Full Text] [Related]
38. Oximes of 3-formylrifamycin SV. Synthesis, antibacterial activity, and other biological properties.
Cricchio R; Lancini G; Tamborini G; Sensi P
J Med Chem; 1974 Apr; 17(4):396-403. PubMed ID: 4151507
[No Abstract] [Full Text] [Related]
39. The ability of airborne Klebsiella pneumoniae to colonize mouse lungs.
Bolister NJ; Johnson HE; Wathes CM
Epidemiol Infect; 1992 Aug; 109(1):121-31. PubMed ID: 1499666
[TBL] [Abstract][Full Text] [Related]
40. [The antibacterial and chemotherapeutic activity of the Soviet produced antibiotic rifamitsina SV].
Shorin VA; Shapovalova SP
Antibiotiki; 1974 Jan; 19(1):3-6. PubMed ID: 4156904
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
